A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

NCT07234591 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis
Moderate to Severe Plaque Psoriasis

Interventions

DRUG: Tyk2 inhibitor
DRUG: Placebo

Sponsor

Usynova Pharmaceuticals Ltd.